CTOR NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Citius Oncology, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic

Open interactive chart View report data Download investor PDF
Latest close 0.56 USD
-18.4% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -35.1% below the Trend Line and sits at 3.8% of its 52-week range. The latest completed week returned -18.4%, after a -9.3% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 51/100. Near-term considerations: earnings are due in 13d.

Setup score 23 out of 100
Latest Close 0.56 USD 24 Jul 2026
1W Return -18.4% latest completed week
4W Return -9.3% short-term follow-through
12W Return -40.5% quarterly tape
Trend Breadth 25.0% 13 of 52 weeks active
Volume Ratio 1.9x vs 13-week average
What is working
  • Volume is elevated versus the 13-week average, confirming attention.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -18.4% Latest completed week; four-week move -9.3%. Indicator stack 14/39 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 42.75% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 51/100 43 relevant articles in the latest sentiment read. Event risk 13d Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -35.1% below the Trend Line and sits at 3.8% of its 52-week range. The latest completed week returned -18.4%, after a -9.3% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.9x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0512-week average 0.06

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure11/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.05Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -9.3% over four weeks, -40.5% over 12 weeks, and -71.5% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-18.4%
4W-9.3%
12W-40.5%
26W-50.2%
52W-71.5%
Active trend streak0 weeks
Active weeks in one year13
Trend breadth25.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.03Latest activity-pressure read.
Pressure change-125.6%Four-week change in activity pressure.
Leadership-57.49Latest relative-leadership reading.
RS change6.1%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 30 Sep 2025 Field coverage 73% Model confidence 70%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength67/100Blend of value, momentum, and quality. Underlying universe rank 34; rank 1 is best.
Value58/100Relative valuation strength. Underlying universe rank 43; rank 1 is best.
Quality56/100Profitability and accounting quality. Underlying universe rank 45; rank 1 is best.
Momentum58/100Medium-term price momentum. Underlying universe rank 43; rank 1 is best.
Growth58/100Revenue and earnings growth. Underlying universe rank 43; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
9.3x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-31.5%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-775.1%
Operating profit retained from revenue.
Free-cash-flow margin
-300.4%
Free cash flow generated from revenue.
Return on invested capital
-89.5%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-3243.6%
Latest one-year free-cash-flow growth.
Piotroski F-score
4/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-29.0%
Net share repurchases relative to market value.
Shareholder yield
-29.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-0.0x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment51/100

Weighted news tone is neutral across 43 relevant articles.

9 positive · 27 neutral · 7 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings13dNext report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-76.3%Distance below the 52-week high.
13-week volatility8.3%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher9 of 2617 weeks finished lower.
Best week+37.4%Week of 3 Apr.
Worst week-20.8%Week of 20 Mar.
Latest week-18.4%Week of 24 Jul.

Shape of recent returns

Strong gains7
Modest gains2
Flat weeks0
Modest losses5
Sharp losses12
Recent vol8.3%13-week weekly-return volatility.
Base vol12.7%52-week weekly-return volatility.
Up/down split21/31Count of positive and negative weeks in the 52-week window.
Average skew10.1% / -9.5%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape24/100

Trend, activity pressure, participation, and risk combine to a 24/100 tape read.

 Indicator analysis28/100

Latest 12-week confirmation: trend 0/12, activity pressure 11/12, relative leadership 0/12.

Activity pressure 0.05; No reversal markers Next-Week ExpectancyNegative 42.75%

Next-week expectancy is negative with a 42.75% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors59/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 93; Small Cap Core rank 49 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment51/100

Weighted news tone is neutral across 43 relevant articles.

Citius Oncology Inc (CTOR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution Insiders50/100

No recent insider transaction evidence is stored.

 Earnings13d

Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 20260.56 USD-18.4%0.87 USD4.85 USD-0.03-57.49628.5KOff
17 Jul 20260.69 USD-0.3%0.88 USD4.91 USD0.11-50.0687.4KOff
10 Jul 20260.69 USD1.6%0.91 USD4.97 USD0.14-52.79352.0KOff
3 Jul 20260.68 USD9.7%0.92 USD5.04 USD0.10-54.4889.0KOff
26 Jun 20260.62 USD-7.4%0.94 USD5.10 USD0.11-61.22252.6KOff
19 Jun 20260.67 USD0.9%0.96 USD5.16 USD0.12-62.35137.5KOff
12 Jun 20260.66 USD-14.9%0.98 USD5.23 USD0.12-62.89638.2KOff
5 Jun 20260.78 USD-2.3%1.00 USD5.29 USD0.24-56.04196.7KOff
29 May 20260.80 USD-5.0%1.02 USD5.35 USD0.28-57.34288.2KOff
22 May 20260.84 USD-12.8%1.05 USD5.41 USD0.31-54.03313.4KOff
15 May 20260.96 USD6.2%1.08 USD5.48 USD0.28-46.89636.0KOff
8 May 20260.91 USD-4.0%1.10 USD5.54 USD0.11-50.31391.0KOff
1 May 20260.94 USD7.7%1.13 USD5.60 USD-0.18-45.57396.2KOff
24 Apr 20260.88 USD-0.1%1.16 USD5.66 USD-0.42-48.88719.5KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.